DDInter222 DDInter381
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) causes {v} (Side Effect) Dyspepsia
Dyspepsia {u} (Side Effect) is caused by {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Duloxetine
Duloxetine {u} (Compound) resembles {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Duloxetine
Duloxetine {u} (Compound) resembles {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Floctafenine
Floctafenine {u} (Compound) resembles {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is associated with {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Cinacalcet
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Terbinafine
Terbinafine {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Cinacalcet
Bortezomib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Cinacalcet
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cinacalcet (Compound)
Bortezomib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Cinacalcet (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Propranolol (Compound) and Propranolol (Compound) resembles Cinacalcet (Compound)
Bortezomib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Propranolol (Compound) and Propranolol (Compound) resembles Cinacalcet (Compound)
Bortezomib (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Duloxetine (Compound) and Duloxetine (Compound) resembles Cinacalcet (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Duloxetine (Compound) and Duloxetine (Compound) resembles Cinacalcet (Compound)
Bortezomib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Floctafenine (Compound) and Floctafenine (Compound) resembles Cinacalcet (Compound)
Bortezomib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is associated with chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Cinacalcet (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Terbinafine and Terbinafine (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Cinacalcet (Compound)
Bortezomib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is associated with chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Cinacalcet (Compound)